Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients

References

• International Agency for Research on Cancer (IARC). IARC Monographs - 100A: Cyclophosphamide. Paris: IARC-WHO; 2012.
   Google Scholar
• de JongeME, van DamSM, HillebrandMJX, et al. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N’,N”-triethylenethio-phosphoramide (thiotepa) and N, N’, N”-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2004;39:262–271. doi:10.1002/jms.57015039933
   PubMed Web of Science ®Google Scholar
• EkhartC, DoodemanVD, RodenhuisS, SmitsPH, BeijnenJH, HuitemaAD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008;18(6):515–523. doi:10.1097/FPC.0b013e3282fc976618496131
   PubMed Web of Science ®Google Scholar
• EmadiA, JonesRJ, BrodskyRA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638–647.19786984
   PubMed Web of Science ®Google Scholar
• HarahapY, SamuelC, AndalusiaR, SyafhanNF. Analysis of 4-hydroxycyclophosphamide in cancer patients plasma for therapeutic drug monitoring of cyclophosphamide. Int J Pharm Pharm Sci. 2016;8(9):194–200. doi:10.22159/ijpps.2016v8i9.12918
   Google Scholar
• NakajimaM, KomagataS, FujikiY, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 2007;17(6):431–445. doi:10.1097/FPC.0b013e328045c4fb17502835
   PubMed Web of Science ®Google Scholar
• ColemanMD. Human Drug Metabolism. 2nd ed. USA: Wiley; 2010.
   Google Scholar
• MehlotraRK, ZiatsMN, BockarieMJ, ZimmermanPA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006;62:267–275.16506047
   PubMed Web of Science ®Google Scholar
• ZangerUM, KleinK. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. doi:10.3389/fgene.2013.0002423467454
   PubMedGoogle Scholar
• de JongeME, HuitemaADR, RodenhuisS, BeijnenJH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135‐1164. doi:10.2165/00003088-200544110-00003
   Web of Science ®Google Scholar
• HelsbyNA, YongM, van KanM, de ZoysaJR, BurnsKE. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. Br J Clin Pharmacol. 2019;1–10.
   Web of Science ®Google Scholar
• HarounF, Al-ShaarL, HabibRH, et al. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2015;75:207–214. doi:10.1007/s00280-014-2632-425428516
   PubMed Web of Science ®Google Scholar
• LangT, KleinK, FischerJ, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399–415. doi:10.1097/00008571-200107000-0000411470993
   PubMedGoogle Scholar
• HiratsukaM, TakekumaY, EndoN, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002;58:417–421. doi:10.1007/s00228-002-0499-512242601
   PubMed Web of Science ®Google Scholar
• LambaV, LambaJ, YasudaK, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther. 2003;307:906–922. doi:10.1124/jpet.103.05486614551287
   PubMed Web of Science ®Google Scholar
• HanantaL, AstutiI, SadewaAH, et al. The Prevalence of CYP2B6 Gene Polymorphisms in Malaria-endemic Population of Timor in East Nusa Tenggara Indonesia. Osong Public Health Res Perspect. 2018;9(4):192–196. doi:10.24171/j.phrp.2018.9.4.0830159225
   PubMedGoogle Scholar
• MelansonSEF, StevensonK, KimH, et al. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010;85(12):967–971. doi:10.1002/ajh.2188921108329
   PubMed Web of Science ®Google Scholar
• ElmaagacliAH, KoldehoffM, SteckelNK, TrenschelR, OttingerH, BeelenDW. Cytochrome P450 2C19 loss of function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant. 2007;40:659–664. doi:10.1038/sj.bmt.170578617680025
   PubMed Web of Science ®Google Scholar
• ZangerUM, KleinK, SausseleT, BlievernichtJ, HofmannM, SchwabM. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743–759. doi:10.2217/14622416.8.7.74317638512
   PubMed Web of Science ®Google Scholar
• XieH, GriskeviciusL, StahleL, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci. 2006;27:54–61. doi:10.1016/j.ejps.2005.08.00816183265
   PubMed Web of Science ®Google Scholar
• AriyoshiN, MiyazakiM, ToideK, SawamuraY-I, KamatakiT. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun. 2001;281:1256–1260. doi:10.1006/bbrc.2001.452411243870
   PubMed Web of Science ®Google Scholar
• XieHJ, YasarU, LundgrenS, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53–61. doi:10.1038/sj.tpj.650015712629583
   PubMed Web of Science ®Google Scholar
• de AndresF, TeranS, HernandezF, TeranE, LLerenaA. To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype–phenotype concordance and discordance in the ecuadorian population. OMICS. 2016;20:699–710. doi:10.1089/omi.2016.014827849442
   PubMed Web of Science ®Google Scholar
• SuG, MinH, XinL, XiaoC, EliC, Shu-FengZ. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res. 2006;23(9):1983–1990. doi:10.1007/s11095-006-9083-516951995
   PubMed Web of Science ®Google Scholar
• SofroASM. Population Genetic Studies in Indonesia [Dissertation]. Canberra: Australian National University; 1982.
   Google Scholar
• Koentjaraningrat. MetodePenelitian Masyarakat. Jakarta: Gramedia Pustaka Utama; 1997.
   Google Scholar
• EMEA. Guideline on Bioanalytical Method Validation. EMEA; 2011.
   Google Scholar
• FDA. Bioanalytical Method Validation Guidance. FDA; 2018.
   Google Scholar
• JoyM, LaM, WangJ, BridgesA, HuY, HoganS. Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol. 2012;74(3):445–455. doi:10.1111/j.1365-2125.2012.04223.x22380717
   PubMed Web of Science ®Google Scholar
• HallOM, PeerCJ, FitzhughCD, FiggWD. A sensitive and rapid ultrahigh - performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxy-cyclophosphamide metabolite in human plasma. J Chromatogr B. 2018;1086:56–62. doi:10.1016/j.jchromb.2018.04.016
   Web of Science ®Google Scholar
• BC Cancer Agency. Cancer Drug Manual: Cyclophosphamide. Canada: BC Cancer Agency; 2013.
   Google Scholar
• HarahapY, YanuarA, CyrilM, MelhanM, PurwantoDJ. Quantification of 3-hydroxypropyl mercapturic acid in the urine of patients with breast cancer to monitor cyclophosphamide toxicity. Ther Drug Monit. 2020;42(4):548–553. doi:10.1097/FTD.000000000000073732079909
   PubMed Web of Science ®Google Scholar
• London Cancer. Guidelines for the Administration of Mesna with Ifosfamide and Cyclophosphamide. London: London Cancer; 2014.
   Google Scholar